As per Future Market Insights’ latest industry analysis, the valuation for the global Spasticity Treatment Market was around US$ 12.2 Billion in 2022 and is projected to exhibit a CAGR growth of close to 8.1% over the forecast period, with an estimated valuation of US$ 28.4 Billion in 2033.

Spasticity is a condition that is characterized by the involuntary tightening or contraction of muscles. It is caused by damage to the central nervous system, which can occur as a result of conditions such as multiple sclerosis, cerebral palsy, spinal cord injury, or stroke. When the muscles are affected by spasticity, they become stiff and difficult to move. This can result in difficulty with movement, coordination, and balance, and can also cause pain and discomfort.

Non-invasive treatments for spasticity, such as physical therapy and occupational therapy, are becoming more popular. These treatments can help to improve range of motion, reduce pain, and enhance overall quality of life without the need for invasive procedures. The prevalence of spasticity is increasing worldwide, which is driving the demand for effective treatment options.

Get a PDF Sample with Latest Market Insights@ https://www.futuremarketinsights.com/reports/sample/rep-gb-17165

As awareness of spasticity is growing, more patients are being diagnosed and seeking treatment, which is causing the market for spasticity treatment to further expand. Advances in technology have led to the development of new and innovative treatment options, such as minimally invasive procedures and non-invasive devices, which are driving the growth of the spasticity treatment market.

Increasing use of botulinum toxin injections is also driving the growth of the market. Botulinum toxin injections have become increasingly popular for the treatment of spasticity. They work by blocking the release of acetylcholine, a neurotransmitter that causes muscles to contract. Botox injections have a lower risk of side effects compared to other treatments, such as oral medications. This is also driving the growth of the market for combination therapies for spasticity treatment.

Overall, these factors are contributing to the growth of the spasticity treatment market, and are expected to continue to drive demand for effective and innovative treatment options in the coming years.

Key Takeaways from Market Study:

• Treatment Type is the leading segment as treatment options are increasing among patients and professionals, and held about 4% market share in 2022, due to significant advances in the development of new treatments for spasticity, including medications, physical therapy, and surgical procedures.
• Cerebral palsy is the leading segment and held about 4% market share in 2022, due to increased incidence of risk factors and increasing prevalence rate of the cerebral palsy.
• By distribution channel, the hospital pharmacies dominated the global spasticity treatment market with holding the total market share of about 3% by the end of 2022, owing to the convenience and ease of accessibility to range of products from OTC/off label products to licensed products.
• By service providers, the hospitals dominated the global spasticity treatment market with holding the total market share of about 1% by the end of 2022, owing to the increasing diagnostic tools and rising inpatient and outpatient services.
• By region, North America is leading in the global spasticity treatment market with U.S. contributing around US$ 3.63 Billion in 2022 to the global market.

“Increasing adoption of combination therapies and growing awareness and diagnosis of the condition to create lucrative potential for the market to grow” says an analyst of Future Market Insights.

Market Competition:

Key players in the axillary hyperhidrosis market expand their businesses through acquisitions, expansion, and collaborations. The focus of major players is on tactics like increasing sales and applying new technologies for the development of novel products.

• In January 2019, GSK and Novartis announced a collaboration to support scientific research into genetic diversity in Africa.
• In July 2022, GSK acquired Sierra Oncology, a California-based biopharmaceutical company.
• In August 2022, Sun Pharma launched a website to expand its long-term care portfolio in the US.

What Does the Report Cover?

Future Market Insights offers a unique perspective and actionable insights on the spasticity treatment market in its latest study, presenting a historical demand assessment of 2012 – 2022 and projections for 2023 – 2033. The global spasticity treatment market is segmented in detail to cover every aspect of the market and present a complete market intelligence approach to the reader.

Key Companies Profiled:

• Medtronic Plc
• Piramal Enterprises Ltd.
• AbbVie, Inc. (Allergan)
• Ipsen Pharma
• F. Hoffmann-La Roche Ltd
• GlaxoSmithKline plc
• Pfizer Inc.
• Elite Pharmaceuticals Inc.
• Orient Pharma
• Acorda Therapeutics, Inc.
• Sun Pharmaceutical Industries Ltd
• Novartis AG (Alcon)
• Teva Pharmaceutical Industries Ltd
• Zydus Cadila Healthcare Ltd.
• Beximco Pharmaceuticals Ltd
• Merz Pharma
• Thought Technology Ltd.
• UltraCare PRO
• Invacare Corporation
• ATI Physical Therapy
• P.T. Services Rehabilitation, Inc.
• Banner Health

Key Segments Covered in Spasticity Treatment Industry Research:

By Diagnosis & Treatment Type:

• Diagnosis
  • Inpatient
  • Outpatient
• Treatment Type
  • Drug
    • Baclofen
    • Tizanidine
    • Dantrolene sodium
    • Diazepam
    • Clonazepam
    • Gabapentin
  • Physical Therapy
  • Botulinum injection
  • Surgery Treatment
  • Other Treatment
• Devices
  • Reciprocal EMG-Triggered Stimulation
  • Transcutaneous Electrical Nerve Stimulation
  • Bracing and Cuff
  • Leg lifter
  • Cane and Crunches
  • Wheelchair
  • Others

By Indication:

• Cerebral Palsy
• Multiple Sclerosis
• Amyotrophic Lateral Sclerosis
• Hereditary Spastic Paraplegias
• Periventricular Leukomalacia
• Metabolic Diseases
• Traumatic Brain Injury
• Spinal Cord Injury
• Stroke
• Multiple System Atrophy
• Stiff-Person Syndrome
• Infectious Transvers Myelitis
• Encephalopathy
• Brain Tumor
• Krabbe Disease
• Johns Hopkins Disease

By Distribution Channel:

• Hospitals Pharmacies
• Retail Pharmacies
• Drug Stores
• Online Pharmacies

By Service Providers:

• Hospitals
• Ambulatory Surgical Centers
• Home Care Settings
• Specialty Clinics
• Diagnostic Centers